```html

Xanthomatous Lymphadenopathy: What It Is, Why It Happens, and How to Manage It

What is Xanthomatous lymphadenopathy?

Xanthomatous lymphadenopathy (XL) is a rare condition in which lymph nodes become enlarged and are filled with lipid‑laden (fat‑containing) macrophages called xanthoma cells. The word “xanthoma” comes from the Greek xanthos, meaning “yellow,” reflecting the yellow‑orange discoloration that can be seen during pathology examination or, occasionally, on the skin surface over the node. XL is not a disease itself; rather, it is a histologic reaction pattern that occurs in a variety of systemic, metabolic, infectious, and neoplastic disorders. Because the swollen nodes may feel firm or rubbery and sometimes are visible under the skin, patients often notice a painless lump in the neck, armpit, groin, or elsewhere.

In most cases the diagnosis of XL is made after a biopsy of an enlarged lymph node, where a pathologist identifies the characteristic foamy macrophages. Understanding the underlying cause is essential because treatment is directed at that primary disorder, not at the xanthomatous change itself.

Common Causes

Below are the most frequently reported conditions that can lead to xanthomatous lymphadenopathy.

• Familial hypercholesterolemia (FH) – severe elevation of LDL cholesterol leads to lipid deposition in nodes.
• Lipoprotein lipase deficiency – inability to clear triglyceride‑rich particles.
• Hypertriglyceridemia (type V familial dysbetalipoproteinemia) – excess chylomicrons and VLDL cause xanthoma formation.
• Chronic granulomatous disease (CGD) – abnormal neutrophil function can produce foamy macrophages in lymphoid tissue.
• Tuberculosis (TB) and atypical mycobacterial infections – chronic infection triggers a granulomatous response that can become xanthomatous.
• Sarcoidosis – non‑caseating granulomas sometimes contain lipid‑laden macrophages.
• Langerhans cell histiocytosis – proliferative disorder of dendritic cells that can involve lymph nodes with xanthomatous change.
• Hodgkin lymphoma (especially nodular sclerosis subtype) – necrosis and lipid release may create a xanthoma‑like appearance.
• Dermatomyositis & other connective‑tissue diseases – immune complex deposition may be accompanied by lipid‑laden macrophages.
• Chronic obstructive liver disease (e.g., cirrhosis) – impaired lipid metabolism results in extra‑hepatic lipid accumulation.

Associated Symptoms

Because XL is usually a manifestation of another disorder, the accompanying symptoms often reflect the underlying disease. Common associated findings include:

• Skin xanthomas – yellowish plaques on elbows, knees, or Achilles tendon.
• Fatigue or malaise – especially in systemic inflammatory or neoplastic conditions.
• Fever or night sweats – typical of infections (TB, atypical mycobacteria) or lymphoma.
• Weight loss or loss of appetite – seen in chronic infections, sarcoidosis, and cancers.
• Chest or abdominal pain – may indicate organ involvement (e.g., pulmonary sarcoidosis, hepatic disease).
• Joint pain or swelling – common in connective‑tissue disorders.
• Elevated lipid panel – high LDL, VLDL, or triglycerides in metabolic causes.
• Respiratory symptoms – cough, shortness of breath in TB or sarcoidosis.

When to See a Doctor

The presence of an enlarged lymph node that does not resolve within 2–4 weeks warrants medical evaluation, especially when any of the following are present:

• Rapid growth of the node or increase in size after a period of stability.
• Pain, tenderness, or warmth over the node (suggests infection).
• Systemic signs such as fever, night sweats, unexplained weight loss, or persistent fatigue.
• Visible yellowish discoloration of the skin over the node or elsewhere on the body.
• History of high cholesterol, familial lipid disorders, or recent changes in lipid‑lowering medication.
• Known exposure to tuberculosis, endemic fungi, or a recent travel history to regions with high infectious risk.
• Any prior diagnosis of lymphoma, sarcoidosis, or autoimmune disease with new lymph node enlargement.

Diagnosis

Diagnosing xanthomatous lymphadenopathy involves a stepwise approach that combines clinical assessment with targeted investigations.

1. Clinical examination

• Location, size, consistency, mobility, and overlying skin changes of the node.
• Search for additional nodes (cervical, axillary, inguinal) and for skin xanthomas.
• Document systemic symptoms and obtain a detailed personal/family medical history.

2. Laboratory tests

• Complete blood count (CBC) with differential – looks for anemia, leukocytosis, or lymphocytosis.
• Lipid profile (LDL, HDL, total cholesterol, triglycerides) – essential for metabolic causes.
• Inflammatory markers (ESR, CRP) – often elevated in infection or inflammatory disease.
• Serologic screening for:
  • HIV, hepatitis B/C (immune‑compromised states).
  • TB interferon‑γ release assay or tuberculin skin test.
  • Autoimmune panels (ANA, anti‑dsDNA, ENA) if connective‑tissue disease suspected.

3. Imaging

• Ultrasound – first‑line for superficial nodes; assesses internal architecture and vascularity.
• CT or MRI – evaluates deep or mediastinal nodes, looks for organ involvement.
• PET‑CT – helpful when lymphoma is a concern; increased metabolic activity suggests malignancy.

4. Tissue sampling

The definitive diagnosis requires a lymph node biopsy.

• Fine‑needle aspiration (FNA) – minimally invasive, may provide cytology but often insufficient for definitive diagnosis of XL.
• Core needle biopsy – yields more tissue, allowing histologic assessment of foamy macrophages.
• Excisional biopsy – removal of the entire node; gold standard when lymphoma or granulomatous disease is on the differential.

Pathology will demonstrate clusters of lipid‑laden (xanthoma) macrophages, often admixed with granulomas, necrosis, or atypical lymphoid cells, depending on the underlying cause.

5. Special studies

• Stains for acid‑fast bacilli (Ziehl‑Neelsen) and fungal organisms.
• Immunohistochemistry (CD15, CD30, CD20, CD3) for lymphoma subtyping.
• Genetic testing for familial lipid disorders (LDLR, APOB, PCSK9 mutations).

Treatment Options

Treatment is directed at the root cause; the xanthomatous change typically resolves when the primary disorder is controlled.

1. Metabolic / Lipid‑related causes

• Lipid‑lowering therapy: high‑intensity statins, ezetimibe, or PCSK9 inhibitors for FH; fibrates or omega‑3 fatty acids for severe hypertriglyceridemia.
• Dietary modifications – low‑saturated‑fat, low‑cholesterol diet, restriction of simple sugars, and weight management.
• Regular monitoring of lipid panels (every 3–6 months) to gauge response.

2. Infectious causes

• Mycobacterial infection: standard 6‑month regimen for TB (isoniazid, rifampin, pyrazinamide, ethambutol) or appropriate antibiotics for atypical mycobacteria.
• Adjunctive corticosteroids may be used in severe inflammatory reactions (e.g., TB meningitis).

3. Autoimmune / Inflammatory diseases

• Systemic steroids (prednisone 0.5–1 mg/kg) to reduce granulomatous inflammation.
• Steroid‑sparing agents (methotrexate, azathioprine, mycophenolate) for chronic sarcoidosis or dermatomyositis.

4. Hematologic malignancies

• Chemo‑immunotherapy regimens tailored to the specific lymphoma (e.g., ABVD for Hodgkin lymphoma).
• Targeted therapies (brentuximab vedotin, checkpoint inhibitors) for refractory disease.
• Radiation therapy for localized bulky nodes when indicated.

5. Supportive & home measures

• Maintain a healthy weight and balanced diet to lessen lipid overload.
• Regular physical activity (150 min/week moderate aerobic exercise) improves lipid metabolism.
• Quit smoking and limit alcohol, both of which exacerbate liver dysfunction and lipid disorders.
• Stay current with vaccinations (influenza, pneumococcal, COVID‑19) to reduce infection risk in immunocompromised patients.

Prevention Tips

While XL itself cannot always be prevented, many underlying conditions are modifiable.

• Screen for familial lipid disorders early: if there is a family history of early heart disease, obtain a lipid panel before age 20 and consider genetic counseling.
• Adopt a heart‑healthy lifestyle: diet rich in fruits, vegetables, whole grains, nuts, and fish; limit red meat and processed foods.
• Control diabetes and metabolic syndrome through weight loss, glucose‑lowering medication, and regular exercise.
• Prompt treatment of infections: seek medical care for persistent cough, night sweats, or unexplained fevers to catch TB or atypical mycobacterial disease early.
• Regular medical follow‑up: patients with known sarcoidosis, autoimmune disease, or prior lymphoma should have scheduled imaging and labs to detect lymph node changes early.
• Avoid exposure to known granulomatous triggers: reduce dust inhalation, use protective equipment in occupations with silica or beryllium exposure.

Emergency Warning Signs

---

**References**

• Mayo Clinic. “Lymphadenopathy.” Mayo Clinic Proceedings, 2023.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Familial Hypercholesterolemia.” 2022.
• Centers for Disease Control and Prevention (CDC). “Tuberculosis (TB) Treatment Guidelines.” 2024.
• World Health Organization (WHO). “Management of Dyslipidaemia.” 2023.
• Cleveland Clinic. “Sarcoidosis – Symptoms and Treatment.” Updated 2024.
• American Society of Hematology. “Guidelines for Diagnosis and Management of Hodgkin Lymphoma.” 2023.
• Journal of Clinical Pathology. “Xanthomatous change in lymph nodes: diagnostic considerations.” 2022.

```